Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Synthesis, Characterization, Anti-Proliferative, and Apoptotic Activity of a Novel Quinazoline-Containing 1,2,3-Triazole Toward Three Human Cancer Cells Publisher Pubmed



Mj Dehghannayeri Mohammad JAVAD ; F Peytam FARIBA ; A Foroumadi ALIREZA ; M Mahdavi MAJID
Authors

Source: Scientific Reports Published:2025


Abstract

A novel quinazoline-containing 1,2,3-triazole (4-TCPA) was synthesized to target VEGFR2 signaling for cancer treatment. Although current VEGFR2 inhibitors exhibit strong anticancer activity, their clinical use is limited due to severe side effects. Structural analysis of effective VEGFR2 inhibitors guided the design of 4-TCPA, ensuring the retention of Erlotinib’s essential pharmacophoric features for optimal receptor binding. The compound was tested for its anticancer efficacy against A549 (lung cancer), MCF7 (breast cancer), K562 (leukemia), and human normal fibroblast HFF2 cells. 4-TCPA demonstrated inhibitory activity in nearly all assays, with IC50 concentrations of 35.70 μM for A549, 19.50 μM for MCF7, 5.95 μM for K562, and 135.2 μM for HFF2. Further in vitro biological evaluations examined its mechanistic impact on EGFR, mTOR, Akt, MAPK, and PIK3CA. Apoptotic activity was assessed through Annexin V/PI double staining and caspase-3/7 activation, confirming its ability to induce both early and late apoptosis. Additionally, real-time quantitative PCR (qRT-PCR) was conducted to evaluate the expression levels of Akt, mTOR, MAPK, PIK3CA, EGFR, and VEGFR2. Results showed that 4-TCPA down-regulates these targets in a time-dependent manner, triggering apoptosis across all tested cancer cell lines. The study suggests that 4-TCPA may serve as a promising anticancer agent due to its targeted VEGFR2 inhibition and apoptotic induction, warranting further investigation. These findings support the potential of 4-TCPA as an effective treatment strategy for various cancers. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. Quinazoline-Based Vegfr-2 Inhibitors As Potential Anti-Angiogenic Agents: A Contemporary Perspective of Sar and Molecular Docking Studies, European Journal of Medicinal Chemistry (2023)
2. Synthesis, Cytotoxicity and 99Mtc-Mibi Tumor Cell Uptake Evaluation of 2-Phenylbenzothiazole Tagged Triazole Derivatives, Future Medicinal Chemistry (2024)
3. Synthesis, Biological Evaluation, and in Silico Study of Novel Coumarin-Quinazoline Analogs As Potential Anti-Angiogenesis Agents, Results in Chemistry (2024)
Experts (# of related papers)
View all Related Experts
Alireza Foroumadi (10)
Mohammad Mahdavi (5)
Other Related Docs
4. Imidazo[1,2-A]Quinazolines As Novel, Potent Egfr-Tk Inhibitors: Design, Synthesis, Bioactivity Evaluation, and in Silico Studies, Bioorganic Chemistry (2023)
5. Novel Quinazolin-4(3H)-One Linked to 1,2,3-Triazoles: Synthesis and Anticancer Activity, Chemical Biology and Drug Design (2018)
6. Novel Quinazolines Bearing 1,3,4-Thiadiazole-Aryl Urea Derivative As Anticancer Agents: Design, Synthesis, Molecular Docking, Dft and Bioactivity Evaluations, BMC Chemistry (2024)
7. Design, Synthesis and Biological Evaluation Of4-(Imidazolylmethyl)- 2-(4-Methylsulfonyl Phenyl)-Quinoline Derivatives As Selective Cox-2 Inhibitors and In-Vitro Anti-Breast Cancer Agents, Iranian Journal of Pharmaceutical Research (2016)
8. A Review on Progression of Epidermal Growth Factor Receptor (Egfr) Inhibitors As an Efficient Approach in Cancer Targeted Therapy, Bioorganic Chemistry (2020)
9. Design, Synthesis, Anticancer Properties, and Molecular Dynamics of New Quinazolinonethioacetohydrazide-1,2,3-Triazoles, Chemistry and Biodiversity (2025)
10. Structure-Based Pharmacophore Design and Virtual Screening for Novel Potential Inhibitors of Epidermal Growth Factor Receptor As an Approach to Breast Cancer Chemotherapy, Molecular Diversity (2018)
11. Synthesis, Molecular Docking, and Cytotoxicity of Quinazolinone and Dihydroquinazolinone Derivatives As Cytotoxic Agents, BMC Chemistry (2022)
12. Synthesis and Antitumor Activity Evaluation of Novel Pyrimidoquinoline Derivatives, Polycyclic Aromatic Compounds (2022)
13. Discovery of Novel 1,2,4-Triazolo-1,2,4-Triazines With Thiomethylpyridine Hinge Binders As Potent C-Met Kinase Inhibitors, Future Medicinal Chemistry (2019)
14. Design and Synthesis of Bmh-21-Like Quinazolinone Derivatives As Potential Anti-Cancer Agents, Journal of Molecular Structure (2024)
15. Design, Synthesis, and Cytotoxic Evaluation of Quinazoline Derivatives Bearing Triazole-Acetamides, Heliyon (2023)
16. Anti-Neoplastic Effects of Aprotinin on Human Breast Cancer Cell Lines: In Vitro Study, Advances in Clinical and Experimental Medicine (2019)
17. Synthesis, Molecular Docking Study, and Cytotoxic Activity of 3,4-Diaryl-5-(4-Pyridinyl)-1,2,4-Oxadiazole, Medicinal Chemistry (2016)
18. Design, Synthesis, and Biological Evaluation of New Series of 2-Amido-1,3,4-Thiadiazole Derivatives As Cytotoxic Agents, Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences (2016)
19. Synthesis, Radiolabeling, and Biodistribution Study of a Novel Dota-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer, Pharmaceutics (2024)
20. N-(5-(Trifluoromethyl)-1,3,4-Thiadiazol-2-Yl)Benzamide and Benzothioamide Derivatives Induce Apoptosis Via Caspase-Dependent Pathway, Pharmaceutical Chemistry Journal (2019)